BMBorja Mora-Peris

Borja Mora-Peris

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Borja Mora-Peris has a total of 229 co-authors. Here are the top co-authors by number of shared publications:

  • Alan Winston

    Division of Infectious Diseases, Department of Medicine

    7 shared publications
  • Alan Winston

    Imperial College London London UK

    7 shared publications
  • Saye Khoo

    Department of Pharmacology, University of Liverpool, Liverpool, UK

    6 shared publications
  • David Back

    Department of Clinical and Molecular Pharmacology, University of Liverpool, Liverpool, UK

    5 shared publications
  • Laura Else

    Department of Clinical and Molecular Pharmacology, University of Liverpool, Liverpool, UK

    4 shared publications
  • Graham Cooke

    Department of Infectious Diseases, Imperial National Health Service (NHS) Healthcare Trust, United Kingdom; Department of Infectious Disease, Imperial College London, United Kingdom

    3 shared publications

Latest Publications

  • Open Access

    Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial

    by Linos Vandekerckhove, Julie Fox, Borja Mora-Peris, Jordi Navarro, Sabine D. Allard, Alison J. Uriel, Santiago Moreno Guillén, Marta Boffito, Frank A. Post, Vicente Estrada, et al.

    HIV persistence in reservoirs despite antiretroviral therapy (ART) is a barrier to a permanent cure. We present the affinity-enhanced TCR bispecific IMC-M113V as a potential therapeutic for targeted HIV reservoir elimination. Preclinical studies demonstrate that IMC-M113V redirects T cells towards cells expressing the variable viral peptide, Gag 77-85, presented by HLA-A*02:01 at low copy number, without binding to HIV-negative cells. Here, we conduct a first-in-human, open-label single ascending dose study of IMC-M113V (1.6-15 µg) in twelve HLA-A*02:01-positive males living with HIV on suppressive ART (EudraCT number 2021-002008-11). Participants receive one intravenous infusion of IMC-M113V on Day 1 and are monitored through Day 29 to evaluate safety, tolerability (primary endpoints) and pharmacodynamic (PD) activity (secondary endpoint). IMC-M113V is well tolerated and not associated with any serious adverse event. PD activity is dose-dependent and strongest in participants with highly IMC-M113V-sensitive Gag 77-85 variant sequences. Thus, we provide a promising foundation to evaluate multiple and higher doses of IMC-M113V as a strategy for achieving ART-free virological control.


  • Open Access

    Parvovirus B19 induced acute severe anaemia in a well-controlled HIV-positive individual

    by Thomas Swaine, Niall Ahmad, Aula Abbara, Borja Mora-Peris, Melissa Wickremasinghe, Christopher Lambert, Anas Khan, Paul Randell


  • Open Access

    HTLV seroprevalence in people using HIV pre-exposure prophylaxis in England

    by Daniel Bradshaw, Arham Khawar, Poorvi Patel, Jennifer Tosswill, Colin Brown, Dana Ogaz, Emily Mason, Roeann Osman, Holly Mitchell, Olamide Dosekun, et al.


  • Open Access

    The clinical presentation of monkeypox: a retrospective case-control study of patients with possible or probable monkeypox in a West London cohort

    by Stephanie Rimmer, James Barnacle, Malick M Gibani, Meng-San Wu, Oshani Dissanayake, Ravi Mehta, Trent Herdman, Mark Gilchrist, David Muir, Umar Ebrahimsa, et al.


  • Top Cited Papers
    Open Access

    Community transmission of monkeypox in the United Kingdom, April to May 2022

    by Roberto Vivancos, Charlotte Anderson, Paula Blomquist, Sooria Balasegaram, Anita Bell, Louise Bishop, Colin S Brown, Yimmy Chow, Obaghe Edeghere, Isaac Florence, et al.

    Between 7 and 25 May, 86 monkeypox cases were confirmed in the United Kingdom (UK). Only one case is known to have travelled to a monkeypox virus (MPXV) endemic country. Seventy-nine cases with information were male and 66 reported being gay, bisexual, or other men who have sex with men. This is the first reported sustained MPXV transmission in the UK, with human-to-human transmission through close contacts, including in sexual networks. Improving case ascertainment and onward-transmission preventive measures are ongoing.


  • Top Cited Papers

    Transmission of monkeypox virus through sexual contact – A novel route of infection

    by Joseph Heskin, Amy Belfield, Charlotte Milne, Nicklas Brown, Yasmin Walters, Christopher Scott, Margherita Bracchi, Luke Sp Moore, Nabeela Mughal, Tommy Rampling, et al.


  • Open Access

    Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial

    by Borja Mora-Peris, Michael R. Keegan, Sujan Dilly Penchala, Jaime H. Vera, Jonathan Underwood, Maryam Khan, Carolina Herrera, Dietmar Fuchs, Adriano Boasso, Saye Khoo, et al.

    Background: Different antiretroviral therapies (ARTs) may have differing effects on central nervous system (CNS) function. We assessed CNS pharmacodynamic effects of switching integrase inhibitors in people-with-HIV (PWH). Methods: PWH on tenofovir-DF/emtricitabine plus raltegravir 400 mg twice daily with suppressed plasma HIV RNA and without overt neuropsychiatric symptoms were randomly allocated on a 1:2 basis to remain on raltegravir or switch to dolutegravir 50 mg once daily for 120 days. Pharmacodynamic parameters assessed included cognitive function (z-score of 7 domains), patient-reported outcome measures (PROMs; PHQ-9 and Beck's depression questionnaires), cerebral metabolite ratios measured by proton magnetic resonance spectroscopy (H-1-MRS) and plasma and cerebrospinal fluid (CSF) HIV RNA. Pharmacokinetic parameters were also assessed in plasma and CSF. Changes and factors associated with changes in pharmacodynamics parameters were assessed. Results:In 20 subjects (19 male, 14 white ethnicity, median age 43 years (IQR: 11.5) and CD4 + count 717 (SD: 298) cells/mu L), over 120 days there were no statistically significant changes in cognitive function [mean z-score difference (95%CI) -0.004 (-0.38/0.37); p = 0.98], PROMs [PHQ-9 median score change: 0 in control arm, -0.5 switch arm (p = 0.57); Beck's depression questionnaire: -1.5 control arm, -1.0 switch arm (p = 0.38)], nor cerebral metabolite ratios between study arms. CSF HIV RNA was <5 copies/mL at baseline and day 120 in all subjects. Geometric mean pre-dose CSF dolutegravir concentration was 7.6 ng/mL (95% CI: 5.2-11.1). Conclusions:Switching integrase inhibitor in virologically suppressed PWH without overt neuropsychiatric symptoms resulted in no significant changes in an extensive panel of CNS pharmacodynamics parameters.

  • Open Access

    Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals

    by Borja Mora-Peris, George Bouliotis, Kulasegaram Ranjababu, Amanda Clarke, Frank A. Post, Mark Nelson, Laura Burgess, Juan Tiraboschi, Saye Khoo, Steve Taylor, et al.

    Maraviroc-intensified antiretroviral therapy (ART) may be associated with cognitive benefits. Therapy-naive, cognitively asymptomatic, HIV-positive individuals were randomly allocated on a 1 : 1 basis to standard ART (Arm1: tenofovir-emtricitabine and atazanavir/ritonavir) or maraviroc intensified ART (Arm2: abacavir-lamivudine and darunavir/ritonavir/maraviroc). Over 48 weeks, detailed assessments of cognitive function tests were undertaken and cerebral metabolites measured using proton magnetic resonance spectroscopy. Our primary endpoint was mean change in cognitive function across treatment arms with factors associated with cognitive function changes also assessed. Of 60 individuals randomized (30 Arm1 and 30 Arm2), 58 were men and 44 of white ethnicity. Treatment groups had similar disease characteristics including overall mean (SD) baseline CD4 cell count 428 (209) and 414 (229) cells/μl, Arms1 and 2, respectively. At week 48, plasma HIV RNA was less than 50 copies/ml in 55 of 56 of those completing study procedures. Cognitive function improved over 48 weeks [mean change z-score (SD) 0.16 (0.09) Arm1 and 0.25 (0.08) Arm2, P = 0.96 for differences between study arms]. A greater increase in frontal grey matter N-acetyl aspartate/creatine ratio was observed in Arm1 [ratio change of 0.071 (SD 0.16)] versus Arm2 [change -0.097 (SD 0.18), P = 0.009], although this was not associated with changes in cognitive function (P = 0.17). Maraviroc-intensified ART had no demonstrable benefit on cognitive function in individuals initiating ART. Greater improvement in neuronal metabolites (N-acetyl aspartate/creatine) was observed with standard ART. Future work should focus on maraviroc-intensified ART in individuals with cognitive impairment.


  • Open Access

    Cognitive Impairment in a Clinical Setting

    by Francesca Ferretti, Borja Mora-Peris, Jonathan Underwood, Adam Waldman, Alex Everitt, Alan Winston


  • Open Access

    Evolution of changes in cognitive function after the initiation of antiretroviral therapy

    by Borja Mora-Peris, Elizabeth Stevens, Francesca Ferretti, Jonathan Underwood, Stephen Taylor, Alan Winston

    Cognitive function is reported to improve after the initiation of combination antiretroviral therapy (cART). Data on the evolution of such changes are limited. We assessed the dynamics of changes in cognitive parameters, in HIV-positive subjects initiating cART. Cognitive function in seven domains was evaluated for HIV-infected patients without clinically significant cognitive impairment prior to the initiation of cART, and 24 and 48 weeks after. Cognitive scores were transformed using standardised z-scores according to the pooled baseline standard deviation. Global, speed, and accuracy composite z-scores were calculated with changes calculated using a paired t test. In 14 subjects, change in global cognitive z-scores from baseline was by 0.08 at week 24 (p = 0.59) and 0.15 at week 48 (p = 0.43). Change in composite speed and accuracy z-scores from baseline at weeks 24/48 were 0.07/0.05 (p = 0.45/0.82) and 0.13/0.23 (p = 0.47/0.45), respectively. In two of the cognitive domains assessing speed (learning and monitoring time), a continued improvement from baseline to weeks 24 and 48 was observed (changes of 0.06–0.08 and 0.10–0.19, respectively), whereas in two domains (detection and identification) an initial improvement at week 24 (changes of −0.10 and 0.04 from baseline, respectively) was followed by a deterioration in score at week 48 (changes of −0.12 and −0.08 from baseline, respectively). None of these changes were statistically significant. A trend for improvement in cognitive function was observed in naïve HIV-positive patients starting cART. The dynamics of this improvement differed both between cognitive domains and the time-points assessed.